KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Intangibles (2016 - 2025)

West Pharmaceutical Services' Intangibles history spans 17 years, with the latest figure at $8.9 million for Q3 2025.

  • For Q3 2025, Intangibles fell 27.64% year-over-year to $8.9 million; the TTM value through Sep 2025 reached $8.9 million, down 27.64%, while the annual FY2024 figure was $10.8 million, 28.48% down from the prior year.
  • Intangibles for Q3 2025 was $8.9 million at West Pharmaceutical Services, down from $9.7 million in the prior quarter.
  • Across five years, Intangibles topped out at $28.7 million in Q1 2021 and bottomed at $8.9 million in Q3 2025.
  • The 5-year median for Intangibles is $16.8 million (2023), against an average of $17.3 million.
  • The largest annual shift saw Intangibles increased 2.14% in 2021 before it tumbled 30.65% in 2022.
  • A 5-year view of Intangibles shows it stood at $23.0 million in 2021, then decreased by 20.0% to $18.4 million in 2022, then fell by 17.93% to $15.1 million in 2023, then fell by 28.48% to $10.8 million in 2024, then dropped by 17.59% to $8.9 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Intangibles are $8.9 million (Q3 2025), $9.7 million (Q2 2025), and $10.0 million (Q1 2025).